Severe Asthma—Perspectives From Adult and Pediatric Pulmonology

Louise Fleming* and Liam Heaney

1 National Heart and Lung Institute, Imperial College, London and Royal Brompton Hospital, London, United Kingdom, 2 Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Institute for Health Sciences, Queens University Belfast, Belfast, United Kingdom

Both adults and children with severe asthma represent a small proportion of the asthma population; however, they consume disproportionate resources. For both groups it is important to confirm the diagnosis of severe asthma and ensure that modifiable factors such as adherence have, as far as possible, been addressed. Most children can be controlled on inhaled corticosteroids and long term oral corticosteroid use is rare, in contrast to adults where steroid related morbidity accounts for a large proportion of the costs of severe asthma. Atopic sensitization is very common in children with severe asthma as are other atopic conditions such as allergic rhinitis and hay fever which can impact on asthma control. In adults, the role of allergic driven disease, even in those with co-existent evidence of sensitization, is unclear. There is currently an exciting pipeline of novel biologicals, particularly directed at Type 2 inflammation, which afford the possibility of improved asthma control and reduced treatment side effects for people with asthma. However, not all drugs will work for all patients and accurate phenotyping is essential. In adults the terms T2 high and T2 low asthma have been coined to describe groups of patients based on the presence/absence of eosinophilic inflammation and T-helper 2 (TH2) cytokines. Bronchosscopic studies in children with severe asthma have demonstrated that these children are predominantly eosinophilic but the cytokine patterns do not fit the T2 high paradigm suggesting other steroid resistant pathways are driving the eosinophilic inflammation. It remains to be seen whether treatments developed for adult severe asthma will be effective in children and which biomarkers will predict response.

Keywords: asthma, children, adults, adherence, type 2 inflammation, biological therapies

INTRODUCTION

Most children and adults diagnosed with asthma can achieve good symptom control on a low dose of correctly administered inhaled steroids with or without additional controller medication. However, there remains a small but significant proportion with ongoing symptoms and/or frequent attacks despite high intensity treatment. This group consume a high proportion of healthcare resources in terms of treatment costs and hospital admissions, as well as the wider societal costs of time of work and school. Direct healthcare costs are mostly due to prescribed medication for asthma
and corticosteroid induced morbidity, particularly in adults (1, 2). In both adults and children, it is essential to firstly confirm the diagnosis of severe asthma in order to implement appropriate management. This article will outline the definition of severe asthma, before exploring the similarities and differences between adults and children in terms of demographics, pathophysiology and management.

**DEFINITION OF SEVERE ASTHMA**

Many terms, including difficult; problematic; therapy resistant and refractory asthma have been used interchangeably with severe asthma. Over the past 20 years national and international organizations have sought to clarify these differences and refine the definitions and nomenclature. The European Respiratory Society (ERS)/American Thoracic Society (ATS) guidelines 2016 (3) set out a framework for the diagnosis of severe asthma in adults and children and more recently the Global Initiative for Asthma (GINA) has produced a useful guide for the diagnosis and management of “Difficult-to-treat” and Severe Asthma in adolescents and adults (4). Only those with a confirmed diagnosis of asthma, prescribed high dose treatment, who have ongoing poor control (or who require a high level of treatment to maintain control) once modifiable factors have been addressed are classified as severe asthma. The diagnosis of asthma is covered elsewhere in this supplement and will not be dealt with further here but identification and addressing poor medication adherence, comorbidities and psychosocial issues is a critical aspect of determining if severe asthma is present and will be discussed below. High intensity standard treatment is generally defined for both adults and children as high dose inhaled corticosteroids (ICS) plus at least one additional controller medication (long acting beta agonist (LABA), theophylline or leukotriene receptor antagonist (LRTA) (5, 6). The definition of high dose ICS is usually stratified by age: children under 5 (or 6) years; between 5 (or 6) to 12 years; and over 12 years. Children and young people (CYP) over 12 years are considered to have severe asthma, although it is accepted there are likely even lower. A study which defined severity on the basis on symptoms, exacerbation frequency and spirometry found that 13% of children with asthma were classified as “severe persistent asthma” (11). However, “difficult to control asthma” would have been a more appropriate label for this group. Of children with difficult to control asthma referred to a specialist severe asthma clinic less than half were assessed as having severe asthma (12). Improvements in assessment of those children, particularly adherence monitoring has seen that figure fall to around 20% (13), suggesting that <2.5% of children with asthma have severe refractory asthma. Severity in pre-school children is even harder to estimate, particularly given the challenges of asthma diagnosis. In the Manchester Asthma and Allergy birth cohort approximately 6% of children with a history of wheeze were classified as severe (14).

**DIFFERENTIATING SEVERE REFRACTORY ASTHMA FROM Milder ASTHMA**

The umbrella term problematic severe asthma or difficult to treat asthma covers all those with ongoing poor control despite high intensity treatment (5, 15, 16). A significant proportion of this group will have improved control once modifiable factors such as adherence, allergen exposure and psychosocial issues are addressed, and co-morbidities identified and managed appropriately (9, 12, 17). Those with ongoing poor control despite attention to these basics of asthma management are considered to have severe asthma, although it is accepted there is overlap between these groups (18).

**POOR ADHERENCE TO MEDICATION**

Poor adherence to ICS, for both adults and children is the most common reason for treatment failure and poor asthma control (19, 20). In adults, 65% of patients with “difficult to control” asthma and prone to exacerbation and referred for specialist assessment in the UK, collected <80% of their inhaled preventive medication (21, 22). Medication issues including poor adherence (from prescription records), poor technique and inappropriate device were assessed as contributing to poor asthma control in half of children with seemingly severe asthma referred to a tertiary center (12). Identification of
poor adherence to inhaled treatment as the primary clinical problem can be difficult. Physician assessment and patient self-report overestimate adherence when compared with objective or surrogate measures such as prescription records (21, 23). Whilst prescription or dispensing records are helpful, these still overestimate adherence as patients may pick up their inhalers and not use them or use them incorrectly. In children, there is a reliance on parents to request and collect prescriptions; and the child must actually take the medication. A US study which sought to determine if azithromycin or montelukast was an inhaled steroid sparing treatment (MARS trial), was abandoned as most of the children were adequately controlled when adherence was addressed under close medical supervision (24). Objective measures for monitoring inhaled medication are available but have been slow to be implemented in routine clinical care. In both adults and children monitoring adherence to inhaled corticosteroids, aligned with biological response—including suppression of fractional exhaled nitric oxide (FeNO) with monitored treatment—can be used to identify patients with poor prior adherence to inhaled corticosteroids who are likely to achieve substantial benefit from optimized inhaled treatment (13, 23, 25, 26). In addition, this approach can identify those subjects who are unlikely to suppress markers of type-2 biology (FeNO and blood eosinophils) with optimized inhaled treatment alone, and would potentially be candidates for biologic (27, 28). Collectively, these studies have shown that at least 50% of adult and 80% of pediatric patients who would qualify for novel biologic therapies based on their exacerbation history and inflammatory biomarkers are simply not taking regular inhaled anti-inflammatory treatment.

However, having identified that adherence is the primary problem, we still need to define the best intervention to change non-adherent behavior in the medium to long-term and there is unlikely to be a “one size fits all” solution. In adults and children there are a number of factors that can influence adherence, both intentional and unintentional (29): The device must be age appropriate and use demonstrated by an appropriately trained team member (30). Unfortunately, even among healthcare professionals, inhaler technique skills are poor (31). A metered dose inhaler (MDI) should always be used with a spacer in children, and all but the youngest children should be able to use a spacer with mouth piece. In children, an additional complexity is the need to engage parents and caregivers in their child's asthma management. The use of remote directly observed therapy using a Smartphone and associated App has demonstrated that children's inhaler technique is generally inadequate, even when use has recently been demonstrated by a specialist children's asthma nurse (32). Ongoing and continued education is needed, particularly as parents often over estimate their child's technique (33). Furthermore, supervision by parents is often poor; 20% of children aged 7 years are not supervised and by 11 years this figure rises to over 50% (34). Interestingly rates of adherence are equally poor among preschool children; younger school aged children and adolescents (13, 35).

Mobile text messaging in chronic disease management improves adherence rates and simple reminder systems have also been shown to improve inhaled maintenance treatment in asthma, suggesting the gains are potentially large in this population (36–38).

Multiple pharmaceutical companies are now involved with digital technologies and "smart inhalers." Monitoring of inhaled treatment may potentially become available across a number of inhaler platforms for asthma patients.

CO-MORBIDITIES

In both adults and children, co-morbidities and psychosocial factors, such as atopy, obesity, gastroesophageal reflux (GER), rhinitis, anxiety disorders, depression, and dysfunctional breathing can negatively impact on asthma control, medication adherence, mimic the symptoms of asthma and contribute to the complexity of asthma management in those with both severe and difficult to treat asthma (10, 18, 39). These should be regarded as "treatable traits" which can be identified and targeted as part of a comprehensive disease management approach (40–44). Table 1 [adapted from Porsbjerg and Menzies-Gow (39)] summarizes these extrapulmonary traits and potential management strategies. The prevalence and importance of many of these comorbidities is much better described in adults than children with asthma (39, 53). Identifying and addressing these multiple factors is critically important because factors such as psychological dysfunction can be a major driver of recurrent exacerbation in this population (60).

The majority of children (>80%) with asthma are sensitized to at least one aeroallergen, and those with severe asthma are likely to have multiple sensitisations (46, 61). In adults, atopy defined by positivity to skin prick testing or specific IgE measurement in severe asthma cohorts is between 60 and 80% (45, 57, 62), with higher prevalence noted in research cohorts. However, atopy with sensitization to Aeroallergens is common in non-asthmatic subjects and in many adults with severe asthma, the role of allergic driven disease even in those with co-existent evidence of sensitization, is unclear. Other atopic conditions such as allergic rhinitis and hay fever are common in children (46) and have been shown to impact on asthma control (63). Chronic rhinosinusitis and nasal polyposis is common in adults, although not children and indeed the presence of nasal polyps in children should be a red flag for an alternative diagnosis such as cystic fibrosis or primary ciliary dyskinesia (9, 45).

Gastro-esophageal reflux (GER) and asthma frequently co-exist in children and adults with asthma (64); however, there is inconsistent evidence of a “cause and effect” relationship between the two GER is associated with asthma symptoms and poor control (65) however, a study of lansoprazole in children with proven GER showed no impact on asthma control (66). A Cochrane review concluded that treatment of GER did not result in an improvement in asthma symptoms in adults or children (67). However, it is possible that non-acid reflux may be important and explain the relationship between symptoms and lack of treatment effect (68).
Obesity is a growing global health problem and can impact on asthma diagnosis, control and exacerbation severity in both adults and children (69, 70). In children the strength of this relationship appears less strong than in adults, although this may in part be because it has been less well-studied (71). There are a number of plausible mechanisms for this relationship: deconditioning leading to breathlessness may mimic asthma symptoms leading to an erroneous asthma diagnosis or assessment of control; lung mechanics are altered in obesity with pulmonary restriction and lower functional residual capacity and ventilatory reserve which can have secondary effects on airway smooth muscle shortening during bronchoconstriction; dysnaptic lung growth (increased in lung volume and airway length but not caliber has been shown to be more common on obese children and associated with worse disease severity and poor response to steroids (72–74). Obesity is also associated with systemic inflammation and IL-6 may be a potential mediator of T2 low asthma (and hence steroid resistance) in some obese patients (75). Furthermore, an adult-onset obese female phenotype has been identified with a link to non-eosinophilic airway inflammation (76). Data from small randomized controlled trials show that weight loss improves asthma control, quality of life and lung function but the overall level of evidence of benefit is low (77, 78) and bariatric surgery has been shown to have a positive effect on asthma outcomes (79–81). The relationship between asthma severity and obesity is further confounded by the fact that steroids lead to weight gain. Thus, it can be difficult to untangle whether obesity is driving asthma symptoms (via the mechanisms described above) or whether persistent symptoms and attacks lead to increased steroid use, causing obesity. Furthermore, weight loss is hindered by steroid use.

Anxiety and depression are both associated with increased exacerbation frequency, poorer asthma control and quality of life (60, 82, 83). A negative life event can increase the risk of an asthma attack within a short time of that event and the effect is magnified if there is a background of chronic stress (84, 85). The precise mechanisms underlying the relationship between stress and severity are not known, however an increased T-helper 2 (TH2) cytokine response has been associated with higher chronic stress and perceived threat in children (86). It may also be that psychological factors such as anxiety and depression along with other mental health conditions may affect a patient’s ability to self-manage their asthma and impact on other behaviors such as smoking and poor adherence.

Dysfunctional breathing (DB) is common in adult patients with severe asthma with a reported prevalence of 19–52% (39, 48). There is good evidence that breathing retraining can improve asthma control and quality of life (87, 88). Much less is known about DB in children. A single study assessing dysfunctional breathing in a pediatric severe asthma clinic found that only 5.4% were found to have a breathing pattern disorder (51). It is likely that DB in under-recognized in children and in the broader population of children with difficult to treat asthma the prevalence is likely much higher. A more comprehensive review of this topic can be found elsewhere in this supplement.

**SMOKING**

Although active cigarette smoking does not appear to be related to the development of adult onset asthma, it is associated

---

**TABLE 1 | Comorbidities in children and adults with severe asthma.**

| Clinical Trait | Adults | Children | Management |
|---------------|--------|----------|------------|
| Obesity       | Patients with severe asthma have a higher BMI than healthy controls and up to 40% are obese (45) | Children with severe asthma have a higher BMI although few children with severe asthma are clinically obese (48) | Weight loss programme; bariatric surgery |
| Depression and anxiety | Anxiety and depression found up to 27% of patients with difficult asthma (9, 47) | High levels of anxiety in both children with severe asthma and their caregivers | Psychological support |
| Breathing pattern disorder (BPD); including vocal cord dysfunction (VCD) | BPD common in difficult asthma, 19–52% (39, 48); VCD reported in up to 50% (49, 50) | One study in children found only 6% of children with severe asthma had BPD; this is likely an underestimate (51), prevalence of VCD unknown | Physiotherapy for BPD and EILD; speech and language therapy for VCD; surgery for supraglottic EILD in selected cases |
| Chronic rhinosinusitis and nasal polyps | Approximately 50% of severe asthma patients have chronic rhinosinusitis; and over 30% nasal polyps (45, 52) | Rare in children; nasal polyps suggest an alternative diagnosis such as cystic fibrosis or primary ciliary dyskinesia | Sinus rinses, nasal steroids, surgery |
| Allergic rhinitis | Allergic sensitization common in severe asthma (approximately 70–80%; and up to 60% report symptoms of allergic rhinitis (although this is similar in milder asthma) Ref Shaw UBiO | Allergic sensitization and allergic rhinitis common in children (up to 80%) (53) | Anti-histamines, nasal steroids |
| Obstructive sleep apnoea (OSA) | Common in severe asthma, up to 92% in one cohort (54), 31% in SARP (65) | Reported prevalence of 63% in poorly controlled asthma secondary to adenotonsillar hypertrophy (59) | CPAP, weight loss, adenotonsillectomy (children) |
| Gastro-esophageal reflux | Common in severe asthma, 17–74% (45, 57, 58) | Diagnosed in 20% of children with severe asthma, although unrelated to any measures of asthma severity (48, 59) | Proton pump inhibitors; little evidence to suggest an impact on asthma symptoms |
with asthma severity, frequent exacerbations and lung function decline (89, 90). Active smoking has been shown to reduce expression of histone deacetylase (HDAC2) via phosoinositide-3-kinase activation, leading to reduced glucocorticoid sensitivity (91). The same has also been found in children with severe asthma exposed to second hand smoke (92).

**THE PATHOBIOLOGY OF SEVERE ASTHMA AND ASThma PHENOTYPES**

Both pediatric and adult severe asthma are characterized by heterogeneity in clinical expression and underlying pathobiological features (Table 2).

In contrast to adults, where a female preponderance is very consistently seen, there is a male preponderance in childhood (47, 97). The increasing proportion of women with severe asthma through the life course is particularly seen in adolescence and around the time of the menopause suggesting a link with female sex hormones (98).

**T2 HIGH AND T2 LOW ASTHMA**

In 1958, Dr. Harry Morrow Brown published a seminal paper in the Lancet, which demonstrated that the clinical response to corticosteroids in adults with chronic persistent asthma was associated with the presence of eosinophils in sputum (99). This study was performed after the United Kingdom Medical Research Council subcommittee on clinical trials in asthma reported no advantage of cortisone acetate in the treatment of chronic asthma, which was a result which many, including Dr. Morrow Brown, found surprising (99). This outcome may have been due in part to the study design and reported outcomes but also in part to the inclusion of a heterogeneous patient population with a clinical diagnosis of asthma. Many years later, a study in adults using sputum samples induced with hypertonic saline also demonstrated that patients with asthma and a sputum eosinophil count ≥3% had a greater response to inhaled corticosteroids (ICS) compared to those with an eosinophil count <3% (100). Woodruff et al. (101) subsequently demonstrated that an IL-13 derived epithelial gene signature (periostin, serpin B2, and CCLA1) was associated with airway eosinophilia and upregulation of T-helper 2 (TH2) cytokines IL-5 and IL-13 but importantly this was only seen in 50% of asthmatics who had withdrawn ICS. Further, reintroduction of ICS was again associated with an improvement in lung function in subjects with evidence of eosinophilia and upregulation of type-2 cytokines, but which importantly was not seen in those subjects without evidence of airway type-2 inflammation/eosinophilia. The authors coined the terms TH2-high and TH2-low asthma and reinvigorated the debate about non-eosinophilic asthma and importantly asthma, which is not responsive to ICS. The classical paradigm was that this process was predominantly driven by TH2 cells however it is now recognized that there are other cellular sources of these cytokines and innate lymphoid cells and mast cells are potential sources of these pro-inflammatory cytokines (102, 103).

Asthma in children is predominantly an atopic disorder. Children with severe asthma are characterized by multiple aeroallergen sensitization, food allergy, high exhaled nitric oxide and progressive loss of lung function throughout childhood (47, 97, 104). Childhood severe asthma is predominantly eosinophilic with increased luminal (bronchoalveolar lavage) and tissue eosinophils (105). However, inflammatory phenotypes based on sputum are not stable in children (106). Furthermore, bronchoscopic studies have demonstrated an absence of TH2 cytokines (105, 107) suggesting that airway eosinophilia in children is mediated by relatively steroid resistance pathways. IL-33 remains elevated despite maximal steroid therapy (108, 109) and increased levels of innate lymphoid cells (ILCs) in children with severe asthma suggests a possible therapeutic target (110). Few studies in children have targeted eosinophils. The only study in children that based management on sputum eosinophils did not show a significant reduction in exacerbations (111), in contrast to benefit demonstrated in adult studies as described above (112).

Bronchoscopic studies in adults have provided rich evidence for underlying pathobiology of adult severe asthma and potential endotypes. Mechanistic studies in children are hampered by ethical constraints: samples from healthy controls have to be opportunistically collected from those having bronchoscopy for upper airway problems or a general anesthetic for an unrelated procedure and it is not possible to repeat bronchoscopies to assess the airway response to an intervention or challenge.

Recent data suggests that steroid resistant type-2 biology in adults is associated with older patients. There is likely to be a degree of overlap but our understanding of inhaled steroid resistant disease has been hampered by our prior failure to measure effective drug delivery in mechanistic studies (25, 113).

**NON-T2 MECHANISMS IN SEVERe ASTHMA**

A study using data form the National Asthma Research Programme in the United States demonstrated that subjects with mild to moderate asthma and no evidence of sputum eosinophilia (defined as sputum eosinophil count <2%) had no improvement in lung function with ICS but showed evidence of a bronchodilator response consistent with asthma (114). This study also identified that in ICS naïve subjects 47% have no evidence of sputum eosinophilia in serial samples taken at various points over a 1-year period but this proportion increased to 72% in subjects currently taking ICS treatment. Taken together, these data suggests that substantial groups of patients with mild and moderate asthma have little evidence of type-2 cytokine driven airway eosinophilia (T2-low asthma) and by extension are likely to have little response to either initiation or escalation ICS treatment. Unfortunately, many patients who are unresponsive to inhaled steroids have their doses relentlessly increased, with no clinical benefit but substantial risk of harm.

McGrath et al. (114) also reported that the patients with non-eosinophilic mild asthma had less bronchial hyperresponsiveness than those with airways eosinophilia and Arron et al. (115) also
demonstrated an inverse relationship between an IL13-high gene signature (T2-high asthma) and bronchial hyperresponsiveness suggesting that T2-low/non-eosinophilic disease is associated with less physiological abnormalities. This is supported by data which suggest that non-eosinophilic asthma is associated with lower risk of asthma exacerbation and there is strong evidence that surrogate biomarkers of type-2 airways inflammation (blood eosinophil count, FeNO, serum ECP, and serum peristin) are all prognostic biomarkers for exacerbation (116–118). In addition, elevated blood eosinophil count and FeNO have consistently been associated with a higher exacerbation rate in the placebo arms of clinical trials in patients with severe asthma unselected on the basis of a pre-stipulated biomarker threshold (119–121). This would suggest that within severe asthma populations, defined using usual diagnostic and treatment criteria, there are subjects with little evidence of active T2-driven disease (type-2 biomarker low), who are persistently symptomatic and defined as uncontrolled asthma, but who have a comparatively low exacerbation risk. However, it is important to comment that severe asthma exacerbations still occur in these symptom high type-2 biomarker low patients albeit at a much lower rate.

It is recognized that ICS will down-regulate type-2 inflammation and related biomarkers (122, 123) and is thus an important confounder in subjects with more severe asthma on ICS treatment raising two important issues—firstly, whether true T2-low asthma exists in more severe asthma, when corticosteroids are down titrated and secondly, what is the mechanism of persistent symptoms in subjects with asthma when type-2 corticosteroid responsive asthma is not present. As discussed above, “true” T2-low asthma appears to be relatively common in mild asthmatic subjects but is generally associated with mild symptoms, less bronchial hyperresponsiveness and a lower risk of asthma exacerbation compared to subjects with T2-high disease. Intuitively, it seems improbable that this group of patients would be progressed to high dose ICS treatment, however if symptoms are persistent and not ICS responsive as appears to be the case, it is possible that some of these patients may be escalated to high intensity treatment to try and improve their symptoms. The issue of whether true T2-low asthma exists in severe asthma is currently being explored in the RASP-UK programme, where patients are having corticosteroids “down titrated” if their biomarkers of T2-driven disease are low (124).

The neutrophilic phenotype is not seen consistently in children (106) and there is evidence to suggest that airway neutrophils may be protective (125) and very little is known about T2 low asthma in children (if it exists at all). Non-atopic clinical phenotypes described in adults including those associated with sensitivity to non-steroidal anti-inflammatory drugs and nasal polyposis are rare in childhood.

### AIRWAY REMODELING

Airway remodeling starts early in childhood asthma. Although no differences in reticular basement membrane (RBM) thickness were seen in infants with respiratory symptoms with or without evidence of reversible airflow obstruction at a median 1 year of age (126) by a median of 3 years there were significant differences between those with troublesome wheeze and healthy controls (127) and by school age the changes were consistent with those seen in adult severe asthma (128). Interestingly, only increased airway smooth muscle in pre-schoolers predicted the persistence of asthma at school age (129). Almost a quarter of children with severe asthma have persistent airflow limitation (PAL), defined as post systemic post-bronchodilator z score ≤ −1.96 for FEV1 (94, 97). In adults this rises to almost 50% and is associated with older age, longer duration of asthma symptoms and airway eosinophilia (93). In children there appears to be no association between PAL and eosinophilic inflammation although there is evidence of an increase in airway smooth muscle surface area and mass in those with PAL (95, 96).
MANAGEMENT

As previously discussed, the first stage of management is the confirmation of the diagnosis of severe asthma and the comprehensive assessment and modification of co-morbidities and factors driving persistent symptoms and asthma attacks. For who remain poorly controlled following this assessment and remain on high intensity conventional treatment (high dose ICS as defined above, plus additional add on treatments including LABA, LRTA or theophylline or maintenance OCS) there is an exciting pipeline of targeted treatments which predominantly target the type-2 cytokine axis including IL-4, IL-5, and IL-13 causing IgE production and eosinophilic inflammation (130, 131).

Omalizumab, the monoclonal antibody to IgE, was the first biologic licensed in the United Sates (US) in 2003 in adults and children (>12 years) and by 2009 it was approved in the US and Europe for all patients with asthma from the age of 6 years. The last 3 years have seen an acceleration in the number of Phase 2 and 3 studies and the licensing of new drugs. The choice of biologic depends on the patient’s age, weight, IgE evaluation (both total and specific), degree of eosinophilia and route of administration. The Global initiative for Asthma (GINA) has recently produced a pocket guide to aid the physician in determining the most appropriate treatment for the individual (4).

OMALIZUMAB

Omalizumab is a recombinant antibody to IgE that diminishes free IgE levels and prevents IgE binding to mast cells and basophils, thus inhibiting degranulation and release of proinflammatory mediators. Studies in adults and children have demonstrated benefit, particularly in terms of reduction in exacerbations (132). The dose is based on IgE level and weight. Approximately 25% of children have an IgE level outside the licensed range and for those at the upper end of the range it may entail 2 weekly injections (97) and additionally adults may not qualify without sensitization to an aeroallergen. The frequency of these scheduled visits must be balanced against a reduction in attacks and hence unscheduled time off school and work. In children omalizumab has also been used seasonally to attenuate the September peak in asthma attacks (133) and this approach showed greatest utility in children on the higher treatment steps. In a randomized withdrawal study, after long-term treatment with omalizumab, patients on omalizumab did better than those randomized to placebo suggesting continuation of omalizumab results in continued benefit and does not support a disease modifying effect of this treatment (134).

DRUGS TARGETING IL-5—MEPOLIZUMAB, RESLIZUMAB, AND BENRALIZUMAB

Mepolizumab is a humanized monoclonal antibody to IL-5 that inhibits eosinophilic maturation and activation. The DREAM and MENSA studies recruited patients with recurrent asthma exacerbations and evidence of eosinophilic inflammation despite high doses of inhaled glucocorticoids and demonstrated a reduction in asthma attacks in those randomized to mepolizumab (135, 136). In subjects with increased blood eosinophil levels, greater efficacy was seen with additional improvements in lung function and symptoms. Although adolescents were recruited for the licensing studies the data were not reported separately and there are no specific pediatric randomized controlled trials. The results of an open label pharmacokinetics and pharmacodynamics study in children aged 6–12 years are awaited (137). Despite this, mepolizumab has recently been licensed by the European Medicines Agency (EMA) for use in patients with severe asthma from 6 years of age. Two further drugs targeting the IL-5 axis have recently been licensed by the EMA for adults: reslizumab and benralizumab. Reslizumab has a similar mode of action to mepolizumab. It binds to IL-5 thus reducing IL-5 mediated maturation and trafficking of eosinophils from the bone marrow as well as inhibiting mediator release and eosinophil apoptosis. It is given by 4 weekly intravenous infusion and demonstrated a significant reduction in exacerbations in the reslizumab arm compared to placebo (138). It is licensed by the Food and Drug Administration (FDA) and EMA for use in adults only and notably studies using a fixed sub-cutaneous dose of 110 mg were negative (139, 140). Benralizumab binds to the IL-5 receptor and in addition to inhibiting growth and activation of eosinophils benralizumab also binds to the Fc receptor on natural killer cells and induces antibody dependent cell mediated cytotoxicity leading to apoptosis of eosinophils. In clinical trials benralizumab led to decreased exacerbations, improved lung function and enhanced quality of life (141, 142). It is theoretically more effective than other IL-5 blockers which allow IL-5 independent migration of eosinophils into the tissue, although superior efficacy was not evident in clinical trials to date and the results of targeting the IL-5 axis seem broadly consistent with reduced exacerbation rates (rescue OCS ≥ 3 days) by approximately 50% and more modest improvements in symptoms and asthma-related quality of life measured and lung function (143). Benralizumab and mepolizumab have also been shown to reduce oral corticosteroid dose compared to placebo with a parallel reduction in exacerbation rate in adult subjects with severe asthma on maintenance oral corticosteroids (144, 145). It also has the advantage of being given every 8 weeks after the initial three, four weekly injections. The FDA have licensed benralizumab for use as an add on treatment for patients with eosinophilic asthma aged 12 years and above. In Europe it has been licensed by the EMA for use in adults only.

DUPILUMAB

Dupilumab binds to the IL-4 receptor-α blocking signaling of IL-4 and IL-13, thus reducing IgE production and eosinophil recruitment. Phase 3 studies have demonstrated a significant reduction in severe exacerbations (47.7% reduction for 200 mg dupilumab compared to placebo, p < 0.001) and additionally...
demonstrated lung function improvement which was evident early after treatment initiation (at week 12, FEV₁ increased 0.14 liters compared to placebo, \( p < 0.001 \)) (120). Dupilumab treatment also resulted in a significant reduction in OCS in adult subjects with severe asthma on maintenance OCS treatment (70.1% with dupilumab vs. 41.9% in the placebo group \( p < 0.001 \) with a 59% lower exacerbation rate than placebo and mean increase in FEV₁ of mean 0.22 liters more than placebo (146). It was licensed in October 2018 by the FDA and in May 2019 by the EMA for use in patients with severe eosinophilic asthma from 12 years of age. It also has a license for treatment of severe atopic eczema and will clearly be a useful treatment in patients with both conditions.

It is disappointing that no data from pediatric specific randomized controlled trials have been presented for mepolizumab, reslizumab, benralizumab or dupilumab and there has been no separate analysis of the adolescents recruited for these studies (likely because of insufficient numbers for meaningful subgroup analysis). Given the challenges recruiting to the MARS trial as discussed above (24), and the inference that there are relatively small numbers of children who have uncontrolled asthma when adherent with standard of care inhaled treatment, it is acknowledged that the feasibility of any such study is challenging and the need for international collaboration essential (147, 148). None-the-less the majority of these drugs have been licensed by the FDA and EMA for 12 years and older and in the case of mepolizumab by the EMA for use from the age of 6 years. In view of the limited add on choices for children with severe asthma, the addition of an increasing number of biologics is to be welcomed. It will be important to use “real-world” outcome data to identify if similar efficacy is seen in pediatric cohorts and to identify markers of response (149). In addition, it has become clear that there is substantial overlap in the populations for these new biologic therapies and randomized pragmatic head to head comparisons between the various biologics will potentially identify which patients should be treated with each drug (149, 150).

**SUMMARY**

There is heterogeneity both within and between pediatric and adult severe asthma. Although there is overlap between the two there are a number of differences in clinical expression and disease mechanisms in children and adults. The impact of the growing lung and developing immune system is likely to account for some of the observable differences however, much remains poorly understood, including the natural history of asthma; adult onset vs. childhood onset disease; and the impact of early life influences (including in utero). Studies such as the Unbiased Biomarkers for the PREDiction of respiratory outcomes (U-BIOPRED) marks a step change in asthma research. Cohorts of preschool, school aged and adults with severe asthma (45, 46) were recruited to this multi-omics study which aims to define phenotypes and endotypes of severe adult and pediatric asthma and preschool wheeze and compare these groups across the life course. In the meantime, there remain a number of unmet needs in the management of severe asthma. Expensive biologics are available to only the minority of patients with severe asthma globally; there is an ongoing disease burden both in terms of asthma related morbidity and mortality and corticosteroids, the mainstay of treatment for many, have an unacceptable side effect profile. Finally, there is the absence to date of any disease modifying treatments. The window of opportunity for such an intervention is likely to lie in very early childhood and therefore to improve the care of all patients with severe disease, there needs to be investment and a focus on research in young children.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

**FUNDING**

LF was an Asthma UK Senior Clinical Fellow and was supported by the Joan Bending, Evelyn Bending, Mervyn Stephens, and Olive Stephens Memorial Fellowship.

**REFERENCES**

1. Barry LE, Sweeney J, O’Neill C, Price D, Heaney LG. The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis. *Respir Res.* (2017) 18:129. doi: 10.1186/s12931-017-0614-x

2. O’Neill S, Sweeney J, Patterson CC, Menzies-Gow A, Niven R, Mansur AH, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. *Thorax.* (2015) 70:376–8. doi: 10.1136/thoraxjnl-2013-204114

3. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. (2018). Available online at: www.ginasthma.org (accessed December 15, 2018).

4. Heaney LG, Conway E, Kelly C, Johnston BT, English C, Stevenson M, et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. *Thorax.* (2003) 58:561–6. doi: 10.1136/thorax.58.7.561

5. Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ, Chung KF, et al. Systematic assessment of difficult-to-treat asthma. *Eur Respir J.* (2003) 22:478–83. doi: 10.1183/09031936.03.00017003

6. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. (2018). Available online at: www.ginasthma.org (accessed December 15, 2018).

7. British Guideline on the Management of Asthma. (2016).

8. Asthma. *Thorax.* (2004) 5:17. doi: 10.1186/1465-9917-5-17

9. Asthma. *Thorax.* (2003) 58:561–6. doi: 10.1136/thorax.58.7.561

10. Heaney LG, Conway E, Kelly C, Johnston BT, English C, Stevenson M, et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. *Thorax.* (2003) 58:561–6. doi: 10.1136/thorax.58.7.561
11. Carroll WD, Lenney W, Child F, Strange RC, Jones PW, Whyte MK, et al. Asthma severity and atopy: how clear is the relationship? Arch Dis Child. (2006) 91:405–9. doi: 10.1136/adc.2005.088278
12. Bracken M, Fleming L, Hall P, Van SN, Bossley C, Biggart E, et al. The importance of nurse-led home visits in the assessment of children with problematic asthma. Arch Dis Child. (2009) 94:780–4. doi: 10.1136/adc.2008.152140
13. Jochemann A, Artusio L, Jalmaledheh A, Nagakumar P, Delgado-Eckert E, Saglani S, et al. Electronic monitoring of adherence to inhaled corticosteroids: an essential tool in identifying severe asthma in children. Eur Respir J. (2017) 50:1700910. doi: 10.1183/13993003.00919-2010
14. Belgrave DCM, Simpson A, Semic-Jusufagic A, Murray CS, Buchan I, Pickles A, et al. Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing. J Allergy Clin Immunol. (2013) 132:575–83.e12. doi: 10.1016/j.jaci.2013.05.041
15. Currie GP, Douglas JG, Heaney LG. Difficult to treat asthma in adults. BMJ. (2009) 338:b499. doi: 10.1136/bmj.b499
16. Lodorup Carlson KC, Hedlin G, Busch A, Wennergren G, de Benedictis FM, De Jongste JC, et al. Assessment of problematic severe asthma in children. Eur Respir J. (2011) 37:432–40. doi: 10.1183/09031936.00091410
17. Bush A, Saglani S. Management of severe asthma in children. Lancet. (2009) 374:251–61. doi: 10.1016/S0140-6736(09)61260-5. Review
18. Bush A, Fleming L, Saglani S. Severe asthma in children. Respir.ology. (2010) 15:258–66. Review
19. Beltrame A, Filippini S, Peana G, Mancini E, et al. Fractional exhaled nitric oxide in the evaluation of treatment escalation in Severe Asthma in children. J Pediatr. (2000) 137:397–401. doi: 10.1136/jp.137.5.397
20. Heaney LG, Horne R. Non-adherence in difficult asthma: time to take it seriously. Thorax. (2012) 67:268–70. doi: 10.1136/thoraxjnll-2011-200257
21. Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of non-adherence in difficult asthma. Am J Respir Crit Care Med. (2009) 180:817–22. doi: 10.1164/rccm.200902-0166OC
22. Murphy AC, Proeschal A, Brightling CE, Wardlaw AJ, Pavord I, Bradding P, et al. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax. (2012) 67:751–3. doi: 10.1136/thoraxjnll-2011-201096
23. Lee J, Tay TR, Radhakrishna N, Hore-Lacy F, Mackay A, Hoy R, et al. Non-adherence in the era of severe asthma biologics and thermoplasty. Eur Respir J. (2018) 51:1701836. doi: 10.1183/13993003.01385-2017
24. Strunk RC, Bacharier LB, Phillips BR, Szefler SJ, Jarlsberg LG, Hill LG, Cabana MD. At what age do children start taking daily asthma medicines on their own? Pediatrics. (2008) 122:e1186–92. doi: 10.1542/peds.2008-0292
25. Klok T, Kaptein AA, Duiverman EI, Brand PL. It’s the adherence, stupid (that determines asthma control in preschool children)! Eur Respir J. (2014) 43:783–91. doi: 10.1183/09031936.00054613
26. Morton RW, Elphick HE, Rigby AS, Dav WJ, King DA, Smith LJ, et al. STAA: a randomised controlled trial of electronic adherence monitoring with reminder alarms and feedback to improve clinical outcomes for children with asthma. Thorax. (2016) 72:347–54. doi: 10.1136/thoraxjnl-2015-208171
27. Thakkar J, Kurup R, Laha TL, Santo K, Thigalingam A, Rogers A, et al. Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis. JAMA Intern Med. (2016) 176:340–9. doi: 10.1001/jamainternmed.2015.7667
28. Tran N, Coffman JM, Sumino K, Cabana MD. Patient reminder systems and asthma medication adherence: a systematic review. J Asthma. (2014) 51:536–43. doi: 10.3109/02770903.2014.888572
29. Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: clinical impact and management. Respirolgy. (2017) 22:651–61. doi: 10.1183/13993003.13026
30. Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. (2016) 47:410–9. doi: 10.1183/13993003.01359-2015
31. Fingleton J, Hardy J, Beaasley R. Treatable traits of chronic airways disease. Curr Opin Pulm Med. (2018) 24:24–31. doi: 10.1097/MCP.0000000000000445
32. McDonald VM, Fingleton J, Agusti A, Hiles SA, Clark VL, Holland AE, et al. Treatable Traits: a new paradigm for 21(st) century management of chronic airway diseases. Eur Respir J. (2019) 53:1802058. doi: 10.1183/13993003.02058-2018
33. Tay TR, Hiew M. Comorbid "treatable traits" in difficult asthma: current evidence and clinical evaluation. Allergy. (2018) 73:1369–82. doi: 10.1111/all.13370
34. McDonald VM, Hiles SA, Godbourt K, Harvey ES, Marks GB, Hiew M, et al. Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respirolgy. (2019) 24:37–47. doi: 10.1183/13993003.13389
35. Shaw DE, Sousa AR, Fowler SJ, Fleming JI, Roberts G, Corfield J, et al. Clinical and inflammatory characteristics of the European Union-BIOPRED adult severe asthma cohort. Eur Respir J. (2015) 46:1308–21. doi: 10.1183/13993003.00779-2015
36. Fleming L, Murray C, Bansal AT, Hashimoto S, Sisgaard H, Busch A, et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J. (2015) 46:1322–33. doi: 10.1183/13993003.00780-2015
37. Chippis BE, Szefler SJ, Simons FE, Haselkorn T, Mink DR, Deniz Y, et al. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol. (2007) 119:1156–63. doi: 10.1016/j.jaci.2006.12.668
38. Heaney LG, Robinson DS. Severe asthma treatment: need for characterising patients. Lancet. (2005) 365:974–6. doi: 10.1016/S0140-6736(05)71087-4
39. Low K, Lau KK, Holmes P, Crossett M, Vallance N, Phyland D, et al. Abnormal vocal cord function in difficult-to-treat asthma. Am J Respir Crit Care Med. (2011) 184:50–6. doi: 10.1164/rccm.201010-1604OC
40. Tay TR, Radhakrishna N, Hore-Lacy F, Smith C, Hoy R, Dabscheck E, et al. Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirolgy. (2016) 21:1384–90. doi: 10.1183/13993003.12838
41. Barker NJ, Jones M, O’Connell NE, Everard ML. Breathing exercises for dysfunctional breathing/hyperventilation syndrome in children. Cochrane Database Syst Rev. (2013) 2013:CD010376. doi: 10.1002/14651858.CD010376.pub2
62. Teague WG, Phillips BR, Fahy JV, Wenzel SE, Fitzpatrick AM, Moore WC, et al. Childhood obesity in relation to poor asthma control. *Thorax.* (2012) 67:582–7. doi: 10.1136/thoraxjnl-2011-201168

63. Paton JY, McCann DC, McGuinness D, Hillary CR, et al. Relationships of active smoking to asthma and asthma severity in the EGEA study. *Thorax.* (2005) 60:876–80. doi: 10.1136/thx.2004.024609

64. Sandberg S, Paton JY, Ahola S, McCann DC. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross sectional analysis of two cohorts. *Lancet Respir Med.* (2016) 4:574–84. doi: 10.1016/s2213-2600(16)30048-0

65. Thakkar K, Boatright RO, Gilger MA, El-Serag HB. Gastroesophageal reflux in difficult asthma: relationship to asthma outcome. *Chest.* (2011) 139:315–23. doi: 10.1378/chest.10-2078

66. Writing Committee for the American Lung Association Asthma Clinical Practice Guideline (part I). *Asthma,* (2013) 68:425–39. doi: 10.1183/13993003.00766-2016

67. Ali Z, Ulrik CS. Obesity and asthma: a coincidence or a causal relationship? A systematic review. *Respir Med.* (2013) 107:1287–300. doi: 10.1016/j.rmed.2013.03.002

68. Silverman RA, Boudreaux ED, Woodruff PG, Clark S, Camargo CA Jr, Cigarette smoking among asthmatic adults presenting to 64 emergency departments. *Chest.* (2003) 123:1277–83. doi: 10.1378/chest.123.5.1277

69. Adeniyi FB, Young T. Weight loss interventions for chronic asthma. *Cochrane Database Syst Rev.* (2012) 2012:CD009339. doi: 10.1002/14651858.CD009339.pub2

70. Akerman MJ, Calacanis CM, Madsen MK. Relationship between asthma severity and obesity. *J Asthma.* (2004) 41:521–6. doi: 10.1081/JAS-120037651

71. Ahmadizar F, Vijverberg SJ, Arets HG, de Boer A, Lang JE, Kattan M, et al. Childhood obesity in relation to poor asthma control and exacerbation: a meta-analysis. *Eur Respir J.* (2016) 48:1063–73. doi: 10.1183/13993003.00766-2016

72. Ali Z, Ulrik CS. Obesity and asthma: a coincidence or a causal relationship? A systematic review. *Respir Med.* (2013) 107:1287–300. doi: 10.1016/j.rmed.2013.03.002

73. Shore SA, Fredberg J. Obesity, smooth muscle, and airway hyperresponsiveness. *J Allergy Clin Immunol.* (2005) 115:925–7. doi: 10.1016/j.jaci.2005.01.064

74. Forno E, Weiner DJ, Mullen J, Sawicki G, Kurland G, Han YY, et al. Obesity and airway dysmampsis in children with and without asthma. *Am J Respir Crit Care Med.* (2017) 195:314–23. doi: 10.1164/rccm.201603-1039OC

75. Peters MC, McGrath KW, Hawkins GA, Hasting AT, Levy BD, Israel E, et al. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. *Lancet Respir Med.* (2016) 4:574–84. doi: 10.1016/s2213-2600(16)30048-0

76. Amelink M, de Nijs SB, de Groot JC, van Tilburg PM, van Spiegel P, Krouwehs FH, et al. Three phenotypes of adult-onset asthma. *Allergy.* (2013) 68:674–80. doi: 10.1111/all.12136

77. Adeniyi FB, Young T. Weight loss interventions for chronic asthma. *Cochrane Database Syst Rev.* (2012) 2012:CD009339. doi: 10.1002/14651858.CD009339.pub2

78. Freitas PD, Ferreira PG, Silva AG, Stelmach R, Carvalho-Pinto RM, Fernandes FL, et al. The role of exercise in a weight-loss program on clinical control in obese adults with asthma. *A randomized controlled trial. Am J Respir Crit Care Med.* (2017) 195:32–42. doi: 10.1164/rccm.201603-0440OC

79. Boulet LP, Turcotte H, Martin J, Poirier P. Effect of bariatric surgery on airway response and lung function in obese subjects with asthma. *Respir Med.* (2012) 106:651–60. doi: 10.1016/j.rmed.2011.12.012

80. Moreira A, Bonini M, Garcia-Larsen V, Bonini S, Del Giacco SR, Agache I, et al. Weight loss interventions in asthma: EAACI evidence-based clinical practice guideline (part I). *Allergy,* (2013) 68:425–39. doi: 10.1111/all.12106

81. Heaney LG, Convay E, Kelly C, Gamble J. Prevalence of psychiatric morbidity in a difficult asthma population: relationship to asthma outcome. *Respir Med.* (2005) 99:1152–9. doi: 10.1016/j.rmed.2005.02.013

82. Eiser MD, Katz PP, Lactao G, Iribarren C. Impact of depressive symptoms on adult asthma outcomes. *Ann Allergy Asthma Immunol.* (2005) 94:566–74. doi: 10.1016/s1081-1206(05)61135-0

83. Mancuso CA, Wenderoth S, Westermann H, Choi TN, Briggs WM, Carlson ME. Patient-reported and physician-reported depressive conditions in relation to asthma severity and control. *Chest.* (2008) 133:1142–8. doi: 10.1378/chest.07-2243

84. Sandberg S, Jarvenpaa S, Penttinen A, McCann DC. Asthma exacerbations in children immediately following stressful life events: a Cox's hierarchical regression. *Thorax.* (2004) 59:1046–51. doi: 10.1136/thx.2004.024604

85. Sandberg S, Paton JY, Ahola S, McCann DC, Guinness D, Hillary CR, et al. The role of acute and chronic stress in asthma attacks in children. *Lancet.* (2000) 356:982–7. doi: 10.1016/s0140-6736(00)02715-x

86. Chen E, Hanso MD, Paton LQ, Griffin MJ, Walker HA, Miller GE. Socioeconomic status and inflammatory processes in childhood asthma: the role of psychological stress. *J Allergy Clin Immunol.* (2006) 117:1104–20. doi: 10.1016/j.jaci.2006.01.036

87. Bruston A, Lee A, Yardley L, Raffery I, Arden-Close E, Kirby S, et al. Physiotherapy breathing retraining for asthma: a randomised controlled trial. *Lancet Respir Med.* (2018) 6:19–28. doi: 10.1016/s2213-2600(17)30474-5

88. Thomas M, Bruston A, Little P, Holgate S, Lee A, Yardley L, et al. A randomised controlled study of the effectiveness of breathing retraining exercises taught by a physiotherapist either by instructional DVD or in face-to-face sessions in the management of asthma in adults. *Health Technol Assess.* (2017) 21:1–162. doi: 10.3310/hta21530

89. Silverman RA, Boudreaux ED, Woodruff PG, Clark S, Camargo CA Jr, Cigarette smoking among asthmatic adults presenting to 64 emergency departments. *Chest.* (2003) 123:1277–83. doi: 10.1378/chest.123.5.1277

90. Siroux V, Pin I, Oryszczyn MP, Le Moural N, Kaufmann F. Relationships of active smoking to asthma and asthma severity in the EGEA study.
Epidemiological study on the Genetics and Environment of Asthma. *Eur Respir J* (2000) 15:470–7. doi: 10.1101/1399-3003.2000.15.08.x

91. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. *FASEB J* (2001) 15:1110–2. doi: 10.1096/fj.00-0432fje

92. Kobayashi Y, Bossley C, Gupta A, Akashi K, Tsartsali L, Mercado N, et al. Passive smoking impairs histone deacetylase-2 in children with severe asthma. *Chest* (2014) 140:305–12. doi: 10.1378/chest.13-0838

93. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. *Am J Respir Crit Care Med* (2001) 164:744–8. doi: 10.1164/ajrccm.164.5.2011026

94. Regamey N, Ochs M, Hilliard TN, Muhlfeld C, Cornish N, Fleming L, et al. Increased airway smooth muscle mass in children with asthma, cystic fibrosis, and non-cystic fibrosis bronchiectasis. *Am J Respir Crit Care Med* (2008) 177:837–43. doi: 10.1164/rccm.200707-977OC

95. Fleming L, Tsartsali L, Wilson N, Regamey N, Bush A. Sputum inflammatory markers of eosinophilic asthma using a composite biomarker algorithm to adjust corticosteroid dose in children. *Thorax* (2017) 72:A4–6. doi: 10.1136/thoraxjnl-2017-210983.78

96. Coburn L, Nagakumar P, Bossley C, Gupta A, De Vries D, Hilliard TN, et al. Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids. *J Allergy Clin Immunol* (2019). 143:104–13.e14. doi: 10.1016/j.jaci.2017.12.1009

97. Nayeem SS, A Bush, LP Silveira, C Bossley, L Fleming. Clinical and pathological characteristics of severely asthmatic children with persistent airflow limitation. *Thorax* (2008) 118:1218–25. doi: 10.1016/j.jaci.2006.08.019

98. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. Dupilumab efficacy and safety in adults with uncontrollable persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet* (2016) 388:31–44. doi: 10.1016/S0140-6736(16)30307-5

99. Heaney LG, Djukanovic R, Woodcock A, Matthews JG, Pavord ID, et al. Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). *Thorax* (2016) 71:187–9. doi: 10.1136/thoraxjnl-2015-207326

100. Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. *J Allergy Clin Immunol* (2013) 132:821–7.e1–5. doi: 10.1016/j.jaci.2013.06.007

101. Bosley C, Saglani S, Kavanagh C, Payne DN, Wilson N, Tsartsali L, et al. Increased airway smooth muscle mass in children with asthma, cystic fibrosis, and non-cystic fibrosis bronchiectasis. *Thorax* (2008) 118:1218–25. doi: 10.1016/j.jaci.2006.08.019

102. Heaney LG, Djukanovic R, Woodcock A, Matthews JG, Pavord ID, et al. Pediatric severe asthma with fungal sensitization is mediated by steroid-resistant IL-33. *J Allergy Clin Immunol* (2015) 136:312–22.e7. doi: 10.1016/j.jaci.2015.01.016

103. Saglani S, Lui S, Ullmann N, Campbell GA, Sherburn RT, Mathie SA, et al. IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma. *J Allergy Clin Immunol* (2013) 132:676–85.e13. doi: 10.1016/j.jaci.2013.04.012

104. Nakagukumar P, Denney L, Fleming L, Bush A, Lloyd CM, Saglani S. Type 2 innate lymphoid cells in induced sputum from children with severe asthma. *J Allergy Clin Immunol* (2016) 137:624–6.e6. doi: 10.1016/j.jaci.2015.06.038

105. Fleming L, Wilson N, Regamey N, Bush A. The use of non-invasive markers of inflammation to guide management in children with severe asthma. *Am J Respir Crit Care Med* (2009) 179:A1305. doi: 10.1164/ajrccm-conference.2009.179.1_MeetingAbstracts.A1305

106. Petsky HL, Cates CJ, Kew KM, Chang AB. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. *Thorax* (2018) 73:1110–9. doi: 10.1136/thoraxjnl-2018-211540

107. Peters MC, Kerr S, Dunican EM, Woodruff PG, Fajt ML, Levy BD, et al. Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids. *J Allergy Clin Immunol* (2019). 143:104–13.e14. doi: 10.1016/j.jaci.2017.12.1009

108. McGarth KW, Itovicov N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. *Am J Respir Crit Care Med* (2012) 185:612–9. doi: 10.1164/rccm.201109-1600OC

109. Arron JR, Scheerens H, Matthews JG. Re defining approaches to asthma: developing targeted biologic therapies. *Adv Pharmacol*. (2013) 66:1–49. doi: 10.1016/S0065-2458(13)60001-9

110. Heaney LG, Djukanovic R, Woodcock A, Matthews JG, Pavord ID, et al. Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids. *J Allergy Clin Immunol* (2019). 143:104–13.e14. doi: 10.1016/j.jaci.2017.12.1009
126. Saglani S, Malmstrom K, Pelkonen AS, Malmberg LP, Lindahl H, Kajosaari M, et al. Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction. *Am J Respir Crit Care Med.* (2005) 171:722–7. doi: 10.1164/rccm.200410-1404OC

127. Saglani S, Payne DN, Zhu J, Wang Z, Nicholson AG, Bush A, et al. Early detection of airway wall remodeling and eosinophilic inflammation in preschool wheezers. *Am J Respir Crit Care Med.* (2007) 176:858–64. doi: 10.1164/rccm.200702-212OC

128. Payne DN, Rogers AV, Adelroth E, Bandi V, Guntupalli KK, Bush A, et al. Early thickening of the reticular basement membrane in children with difficult asthma. *Am J Respir Crit Care Med.* (2003) 167:78–82. doi: 10.1164/rccm.200205-414OC

129. O’Reilly R, Ullmann N, Irving S, Bossley CJ, Sonnappa S, Zhu J, et al. Increased airway smooth muscle in preschool wheezers who have asthma at school age. *J Allergy Clin Immunol.* 2012. doi: 10.1016/j.jaci.2012.08.044

130. Pepper AN, Renz H, Casale TB, Garn H. Biologic Therapy and Novel Molecular Targets of Severe Asthma. *J Allergy Clin Immunol Pract.* (2017) 5:909–16. doi: 10.1016/j.jaip.2017.04.038

131. Fajt ML, Wenzel SE. Biologic therapy in asthma: entering the new age of personalized medicine. *J Asthma.* (2014) 51:669–76. doi: 10.3109/02770903.2014.910221

132. Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. *Cochrane Database Syst Rev.* (2014) 1:CD003559. doi: 10.1002/14651858.CD003559.pub4

133. Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes S, Jr., Calatroni A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. *J Allergy Clin Immunol.* (2015) 136:1476–85. doi: 10.1016/j.jaci.2015.09.008

134. Ledford D, Busse W, Trzaskoma B, Omachi TA, Rosen K, Chippps BE, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. *J Allergy Clin Immunol.* (2017) 140:162–9.e2. doi: 10.1016/j.jaci.2016.08.054

135. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet.* (2012) 380:651–9. doi: 10.1016/S0140-6736(12)60988-X

136. Ortega HG, Liu MC, Pavord ID, Bruselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med.* (2014) 371:1198–207. doi: 10.1056/NEJMoa1403290

137. Asthma. Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children. (2018). Available online at: https://clinicaltrials.gov/ct2/show/NCT02377427 (accessed March 15, 2019).

138. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Bruselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet Respir Med.* (2015) 3:355–66. doi: 10.1016/S2213-2600(13)0042-9

139. Asthma. An Efficacy and Safety Study of Reslizumab Subcutaneously in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils. (2018). Available online at: https://clinicaltrials.gov/ct2/results?cond=&term=NCT02501629&ctry=&state=&city=&dist= (accessed March 15, 2019).

140. Asthma. Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils. (2018). Available online at: https://clinicaltrials.gov/ct2/results?cond=&term=NCT02452190&ctry=&state=&city=&dist= (accessed March 15, 2019).

141. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-doseage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. *Lancet.* (2016) 388:2115–27. doi: 10.1016/S0140-6736(16)31322-8

142. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet.* (2016) 388:2128–41. doi: 10.1016/S0140-6736(16)31322-8

143. Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL-5 therapies for asthma. *Cochrane Database Syst Rev.* (2017) 9:CD010834. doi: 10.1002/14651858.CD010834.pub3

144. Bel EH, Wenzel SE, Thompson PJ, Praza CM, Keene ON, Yancew SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *N Engl J Med.* (2014) 371:1189–97. doi: 10.1056/NEJMoa1403291

145. Nair P, Wenzel SE, Bade KE, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. *N Engl J Med.* (2017) 376:2448–58. doi: 10.1056/NEJMoa1703501

146. Rabe KF, Nair P, Busselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. *N Engl J Med.* (2018) 378:2475–85. doi: 10.1056/NEJMoa1804093

147. Liu NM, van Aalderen W, Carlser KCL, Coleman C, Chalmers JD, Cunningham S, et al. Severe Paediatric Asthma Collaborative in Europe (SPACE): protocol for a European registry. *Breathe.* (2018) 14:93–8. doi: 10.1183/20734735.002018

148. Rusconi F, Fernandes RM, Pijnenburg MWH, Grigg J, Collaboration SCR, European Lung Foundation severe asthma patient advisory g. The Severe Paediatric Asthma Collaborative in Europe (SPACE) ERS Clinical Research Collaboration: enhancing participation of children with asthma in therapeutic trials of new biologics and receptor blockers. *Eur Respir J.* (2018) 52:1801665. doi: 10.1183/13993003.01665–2018

149. Saglani S, Bush A, Carroll W, Cunningham S, Fleming L, Gaillard E, et al. Biologics for paediatric severe asthma: trick or TREAT? *Lancet Respir Med.* (2019) 7:294–6. doi: 10.1016/S2213-2600(19)30045-1

150. Pilette C, Brightling C, Lacombe D, Bruselle G. Urgent need for pragmatic trial platforms in severe asthma. *Lancet Respir Med.* (2018) 6:581–3. doi: 10.1016/S2213-2600(18)30291-1

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Fleming and Heaney. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.